Abstract 1937
Background
Soft tissue sarcoma (STS) has been treated by achieving safe surgical margin rather than by using adjuvant radiotherapy (RT) in our country and 2-cm wide margin can be considered as adequate margin according to Kawaguchi’s criteria. We evaluated local recurrence (LR) and prognosis following resection of high-grade large STS using JOA surgical margin concept.
Methods
Treatment strategy: Surgical resection with at least 2cm-wide margin was attempted whenever possible. Marginal or 1cm-wide margin are acceptable when preserving neurovascular bundles. RT is conducted postoperatively for marginal or R1 margin. Chemotherapy is indicated for patients less than 60 years old with deep seated, high grade and large tumor. PATIENTS: Inclusion criteria are localized STS in the extremities or trunk, larger than 5cm, FNCLCC grade 2 or 3, limb sparing surgery, primary complete resection at our institution, and minimum 3 years of follow-up. We retrospectively analyzed 69 patients treated between 2007 and 2014.
Results
Median follow-up was 64 months. Median tumor size was 8.7cm. 6 patients underwent postoperative RT due to inadequate surgical margin. 21 (30%) patients received chemotherapy. There were 7 (10%) LR with average 14.5 months after surgery. Average size of tumor developing LR (14.8cm) was statistically larger than that without LR (9.8cm, p < 0.05). Only 1 of 9 patients developed LR after postoperative RT for inadequate resection. Distant metastasis was shown in 14 patients with average 20 months after surgery. There was no statistical difference of LR-free and overall survival between wide resection alone and inadequate resection with postoperative RT. Chemotherapy did not significantly affect overall survival.
Conclusions
In this series of high-grade large STS, resection alone with 2cm-wide margin led to good local control, which is identical to previous reports with surgery plus RT. Adjuvant RT should be given for resection with marginal margin or R1 margin of the resected specimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract
5995 - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: Poster Display session 1
Resources:
Abstract
2961 - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma
Presenter: Weiping Liu
Session: Poster Display session 1
Resources:
Abstract
5771 - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center
Presenter: Vadim Lesan
Session: Poster Display session 1
Resources:
Abstract
1165 - Risk factors for Bacteremia-Associated Mortality of Aeromona sobria in Hematologic Malignancies
Presenter: Gabriel De la Cruz-Kú
Session: Poster Display session 1
Resources:
Abstract
5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study
Presenter: Hyunkyung Park
Session: Poster Display session 1
Resources:
Abstract
1886 - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care
Presenter: Severine Coquerelle
Session: Poster Display session 1
Resources:
Abstract
1940 - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1946 - Is bone marrow examination indispensible in chronic myeloid Leukemia at diagnosis ?
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India
Presenter: Debmalya Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract